ICP
GMAB icon

Interchange Capital Partners’s Genmab GMAB Stock Holding History

Interchange Capital Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-243
Closed -$9K – 574
2020
Q4 		$9K Buy
+243
New +$9.08K ﹤0.01% 815

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Interchange Capital Partners's GMAB Position: Q1 2021 in Review

Interchange Capital Partners sold out of Genmab (GMAB) in Q1 2021, closing a stake of 243 shares — an estimated $9K sold.

Interchange Capital Partners first reported a position in GMAB in Q4 2020 and held it in 1 quarter. The position peaked at $9K in Q4 2020. 209 funds tracked by Wall St. Rank hold GMAB as of Q1 2021.

  • Interchange Capital Partners reported no remaining Genmab position as of Q1 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 243 Genmab shares in Q1 2021, an estimated $9K.
  • Interchange Capital Partners first reported a position in Genmab in Q4 2020 and held it in 1 quarter.
  • Interchange Capital Partners's Genmab position peaked at $9K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Genmab as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.